Copenhagen, Denmark; October 29, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today topline results from the Phase III MAIA study (MMY3008) of daratumumab in combination with lenalidomide and dexamethasone (DRd) versus Rd alone as treatment for newly diagnosed patients who are not candidates for high dose chemotherapy and autologous stem …
Tag Archives: genmab
October, 2018
July, 2018
-
12 July
Genmab Partners with Immatics for Development of Next Generation Bispecific Cancer Immunotherapies
Copenhagen, Denmark; July 12, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into a research collaboration and exclusive license agreement with privately owned Immatics Biotechnologies GmbH (Immatics), to discover and develop next-generation bispecific immunotherapies to target multiple cancer indications. The deal strengthens Genmab’s position in immuno-oncology by …
September, 2017
-
8 September
Seattle Genetics Presents Promising Data with Tisotumab Vedotin in Cervical Cancer
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that preliminary clinical data for tisotumab vedotin from a Genmab-sponsored phase 1/2 clinical trial (GEN701) are being featured in an oral presentation at the European Society for Medical Oncology (ESMO) Congress being held September 8-12, 2017 in Madrid, Spain. Additional data from …
August, 2017
-
24 August
Genmab’s Daratumumab Meets Primary Endpoint in Late-Stage Multiple Myeloma Study
Copenhagen, Denmark; August 24, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today topline results from the Phase III ALCYONE study (MMY3007) of daratumumab in combination with bortezomib, melphalan and prednisone (VMP) versus VMP alone as front line treatment for newly diagnosed patients who are not considered candidates for autologous stem …
March, 2017
-
30 March
Genmab Discontinues Mid-Stage Non-Hodgkin’s Lymphoma Study
Copenhagen, Denmark; March 30, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its collaboration partner for daratumumab, Janssen Biotech, Inc., has decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL). The study …
November, 2016
-
22 November
Genmab Announces FDA Approval of Darzalex for Treatment of Multiple Myeloma
Copenhagen, Denmark; November 21, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today the U.S. Food and Drug Administration (FDA) has approved the use of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least …
August, 2016
-
31 August
FDA Expands Approval of Genmab, Novartis’ Arzerra in CLL
Copenhagen, Denmark; August 31, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of ofatumumab (Arzerra®) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic …
-
12 August
Genmab Licenses DuoBody Technology Platform to Gilead for Bispecific Antibody Against HIV
Copenhagen, Denmark; August 10, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today it has entered an agreement to grant Gilead Sciences, Inc. an exclusive license and an option on a second exclusive license, to use the DuoBody® technology platform to create and develop bispecific antibody candidates for a therapeutic …
July, 2016
-
26 July
FDA Grants Breakthrough Therapy Designation to Janssen and Genmab’s Multiple Myeloma Drug
Copenhagen, Denmark; July 26, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for DARZALEX® (daratumumab) injection in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have …
April, 2016
-
1 April
Genmab Announces Positive Interim Results in Phase III Multiple Myeloma Study
Copenhagen, Denmark; March 30, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the Phase III Castor study (MMY3004) of daratumumab in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma met the primary endpoint of improving progression free survival (PFS) …